drugset / Trial / NCT07463846
A Study to Evaluate ALN-2232 in Participants With Obesity
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Timeline
- Start
- 2026-03-02
- Primary completion
- 2027-04-27
- Completion
- 2028-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALN-2232 | Unknown | — | Subcutaneous |
| Subject | Tirzepatide | Peptide | — | Subcutaneous |